Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$140.43 USD

140.43
1,066,874

-2.57 (-1.80%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $140.34 -0.09 (-0.06%) 6:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (87 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

All You Need to Know About Masimo (MASI) Rating Upgrade to Strong Buy

by Zacks Equity Research

Masimo (MASI) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?

by Zacks Equity Research

Alcon sees growth from surgical innovation and vision care products, but faces macro pressures and fierce competition.

Zacks Equity Research

Is it the Right Time to Retain Abbott Stock in Your Portfolio?

by Zacks Equity Research

ABT's strong Nutrition, Diabetes Care and EPD growth fuel momentum, but macro and currency headwinds challenge its outlook.

Zacks Equity Research

Baxter Stock Slips Despite Latest Launch to Boost Patient Monitoring

by Zacks Equity Research

BAX launches FDA-cleared Connex 360 monitor, aiming to boost frontline care and streamline patient monitoring.

Zacks Equity Research

Alcon's UNITY VCS Shows Superior Efficiency in Studies, Stock Up

by Zacks Equity Research

ALC's UNITY VCS shows faster, more efficient cataract and vitreoretinal surgery results, lifting shares after study presentations.

Zacks Equity Research

Here's Why Masimo (MASI) is a Strong Growth Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

LH Stock Rises on Acquisition of BioReference Health's Select Assets

by Zacks Equity Research

Labcorp's $225M acquisition of BioReference Health select assets boosts its oncology diagnostics portfolio and expands patient access nationwide.

Zacks Equity Research

The New Olink Target 48 Neurodegeneration Panel May Boost TMO Stock

by Zacks Equity Research

Thermo Fisher unveils the Olink Target 48 Neurodegeneration panel to accelerate biomarker research in neurodegenerative diseases.

Zacks Equity Research

Should You Continue to Hold Integra Stock in Your Portfolio Now?

by Zacks Equity Research

IART shows strong demand in neurosurgery and Tissue Technologies but faces macro and liquidity challenges.

Zacks Equity Research

Is it a Prudent Move to Retain MYGN Stock in Your Portfolio Now?

by Zacks Equity Research

Myriad Genetics expands oncology testing and launches new diagnostics, but inflation and rising competition weigh on its outlook.

Zacks Equity Research

QGEN Stock Gains From CE-IVDR Certification for QIAstat-Dx Portfolio

by Zacks Equity Research

QIAGEN secures CE-IVDR certification for its full QIAstat-Dx portfolio, boosting its diagnostics arm and lifting shares.

Zacks Equity Research

Exact Sciences Launches Cancerguard MCED Blood Test, Stock Climbs

by Zacks Equity Research

EXAS introduces Cancerguard, a blood test that detects more than 50 cancers, sending shares up after its U.S. debut.

Zacks Equity Research

Should You Add IDEXX Stock to Your Portfolio Right Now?

by Zacks Equity Research

IDXX shows strong CAG Diagnostics growth, cloud software momentum and global expansion but faces solvency and macro risks.

Zacks Equity Research

CRL Stock Rises Following New Strategic Oncology Collaborations

by Zacks Equity Research

Charles River shares rise after new collaborations with PICI and CHLA, boosting its oncology and cell therapy pipeline momentum.

Zacks Equity Research

Here's Why You Should Add NVST Stock to Your Portfolio Right Now

by Zacks Equity Research

Envista's global expansion, strategic acquisitions, and solid solvency boost growth outlook despite FX headwinds.

Zacks Equity Research

Should You Continue to Hold EXAS Stock in Your Portfolio?

by Zacks Equity Research

Exact Sciences sees growth in Cologuard and Oncotype DX, but rising costs and tough competition weigh on EXAS shares.

Zacks Equity Research

Here's Why You Should Add PAHC Stock to Your Portfolio Right Now

by Zacks Equity Research

Phibro Animal Health posts strong Animal Health sales growth, aided by a Zoetis acquisition, while Mineral Nutrition and Performance Products rebound.

Zacks Equity Research

ILMN Stock to Gain From the Launch of Illumina Protein Prep Assay

by Zacks Equity Research

The Illumina Protein Prep rollout boosts multiomics, strengthens disease insights and supports ILMN stock momentum.

Zacks Equity Research

Should You Hold Onto Globus Medical Stock in Your Portfolio for Now?

by Zacks Equity Research

GMED rides strong musculoskeletal demand and new launches, but faces currency headwinds and fierce competition.

Zacks Equity Research

Is it the Right Time to Add CRL Stock to Your Portfolio Now?

by Zacks Equity Research

Charles River's DSA growth, acquisitions and collaborations support momentum, but forex and macro headwinds weigh on its outlook.

Zacks Equity Research

New Strong Buy Stocks for September 4th

by Zacks Equity Research

LRN, RL, ATRO, MASI and BYD have been added to the Zacks Rank #1 (Strong Buy) List on September 4, 2025.

Zacks Equity Research

QIAGEN Stock May Benefit From the US Clearance of QIAstat-Dx Rise

by Zacks Equity Research

QGEN announces the launch of FDA-cleared QIAstat-Dx Rise, which may boost U.S. diagnostic access and testing capacity worldwide.

Zacks Equity Research

Is it Worth Retaining ResMed Stock in Your Portfolio Now?

by Zacks Equity Research

RMD's Mask and Device sales fuel growth, but macro headwinds and fierce competition continue to challenge its performance.

Zacks Equity Research

Charles River Stock May Benefit From Joining EASYGEN Consortium

by Zacks Equity Research

CRL joins EASYGEN to speed CAR-T therapy delivery, which may boost patient access and investor sentiment.

Zacks Equity Research

Is it Apt to Hold Bio-Rad Stock in Your Portfolio Now?

by Zacks Equity Research

BIO's strong ddPCR growth and solid diagnostics demand support its stock despite market pressures and stiff competition.